See more : Alpine Summit Energy Partners, Inc. (ALPS-U.V) Income Statement Analysis – Financial Results
Complete financial analysis of Aileron Therapeutics, Inc. (ALRN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aileron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bitdeer Technologies Group (BTDR) Income Statement Analysis – Financial Results
- Pendrell Corporation (PCOA) Income Statement Analysis – Financial Results
- Pinnacle Bank (PBNK) Income Statement Analysis – Financial Results
- Zhejiang Huamei Holding CO., LTD. (000607.SZ) Income Statement Analysis – Financial Results
- HH&L Acquisition Co. (HHLA-UN) Income Statement Analysis – Financial Results
Aileron Therapeutics, Inc. (ALRN)
About Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.35M |
| Cost of Revenue | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 9.33M | 12.23M |
| Gross Profit | -119.00K | -169.00K | -121.00K | -163.00K | -155.00K | -218.00K | -95.00K | -232.00K | -325.00K | -9.33M | 10.12M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45.29% |
| Research & Development | 3.99M | 17.97M | 17.01M | 11.17M | 17.66M | 18.45M | 14.24M | 10.28M | 7.83M | 9.33M | 12.23M |
| General & Administrative | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.36M | 9.68M | 9.60M | 9.33M | 12.29M | 13.45M | 8.77M | 7.89M | 5.06M | 6.70M | 6.84M |
| Other Expenses | 928.00K | 318.00K | 441.00K | -800.00K | 0.00 | 0.00 | 0.00 | -18.17M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 6.70M | 6.84M |
| Cost & Expenses | 16.28M | 27.65M | 26.61M | 20.50M | 29.96M | 31.90M | 23.01M | 18.17M | 12.89M | 16.03M | 19.07M |
| Interest Income | 0.00 | 0.00 | 0.00 | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 119.00K | 169.00K | 121.00K | 163.00K | 155.00K | 218.00K | 95.00K | 232.00K | 325.00K | 585.00K | 774.00K |
| EBITDA | -15.61M | -27.48M | -26.48M | -20.33M | -29.80M | -31.33M | -23.01M | -17.94M | -12.57M | -15.44M | 4.06M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 18.16% |
| Operating Income | -16.28M | -27.65M | -26.61M | -20.50M | -29.96M | -31.90M | -23.01M | -18.17M | -12.89M | -16.03M | 3.28M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.69% |
| Total Other Income/Expenses | 544.00K | 318.00K | 441.00K | -661.00K | 587.00K | 355.00K | 404.00K | 46.00K | 13.00K | 10.00K | 6.00K |
| Income Before Tax | -15.73M | -27.33M | -26.21M | -21.16M | -29.37M | -31.55M | -22.60M | -18.12M | -12.88M | -16.02M | 3.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.72% |
| Income Tax Expense | 0.00 | -318.00K | -441.00K | 661.00K | -587.00K | 355.00K | 34.00K | 0.00 | 0.00 | 43.00K | 3.10M |
| Net Income | -15.73M | -27.01M | -25.76M | -21.82M | -28.78M | -31.55M | -22.60M | -18.12M | -12.88M | -16.07M | 194.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.87% |
| EPS | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -845.63 | 10.21 |
| EPS Diluted | -3.42 | -5.95 | -5.80 | -12.52 | -23.46 | -42.81 | -60.74 | -33.21 | -23.60 | -844.96 | 10.85 |
| Weighted Avg Shares Out | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.00K | 19.00K |
| Weighted Avg Shares Out (Dil) | 4.60M | 4.54M | 4.44M | 1.74M | 1.23M | 736.91K | 372.15K | 545.72K | 545.72K | 19.02K | 17.89K |
Aileron Therapeutics Announces $35.9 Million Registered Direct Offering
ALRN Stock: What Investors Should Know About Aileron Therapeutics
Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
INVESTEC AUSTRALIA PROPERTY FUND – Release of Explanatory Memorandum and Independent Expert’s Report and Withdrawal of Statements - SENS
MyoKardia Heart Trial, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:MYOK)
Hoth Therapeutics (NASDAQ:HOTH) and Aileron Therapeutics (NASDAQ:ALRN) Head-To-Head Comparison
Analysts Expect Aileron Therapeutics Inc (NASDAQ:ALRN) to Post -$0.16 Earnings Per Share
C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
Aileron Therapeutics’ (ALRN) Buy Rating Reiterated at HC Wainwright
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Source: https://incomestatements.info
Category: Stock Reports